Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo
Top Cited Papers
Open Access
- 1 August 2001
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (15) , 6969-6976
- https://doi.org/10.1128/jvi.75.15.6969-6976.2001
Abstract
Recombinant adeno-associated virus (rAAV) vectors stably transduce hepatocytes in experimental animals. Although the vector genomes are found both as extrachromosomes and as chromosomally integrated forms in hepatocytes, the relative proportion of each has not yet been clearly established. Using an in vivo assay based on the induction of hepatocellular regeneration via a surgical two-thirds partial hepatectomy, we have determined the proportion of integrated and extrachromosomal rAAV genomes in mouse livers and their relative contribution to stable gene expression in vivo. Plasma human coagulation factor IX (hF.IX) levels in mice originating from a chromosomally integrated hF.IX-expressing transposon vector remained unchanged with hepatectomy. This was in sharp contrast to what was observed when a surgical partial hepatectomy was performed in mice 6 weeks to 12 months after portal vein injection of a series of hF.IX-expressing rAAV vectors. At doses of 2.4 × 10 11 to 3.0 × 10 11 vector genomes per mouse ( n = 12), hF.IX levels and the average number of stably transduced vector genomes per cell decreased by 92 and 86%, respectively, after hepatectomy. In a separate study, one of three mice injected with a higher dose of rAAV had a higher proportion (67%) of integrated genomes, the significance of which is not known. Nevertheless, in general, these results indicate that, in most cases, no more than ∼10% of stably transduced genomes integrated into host chromosomes in vivo. Additionally, the results demonstrate that extrachromosomal, not integrated, genomes are the major form of rAAV in the liver and are the primary source of rAAV-mediated gene expression. This small fraction of integrated genomes greatly decreases the potential risk of vector-related insertional mutagenesis associated with all integrating vectors but also raises uncertainties as to whether rAAV-mediated hepatic gene expression can persist lifelong after a single vector administration.Keywords
This publication has 68 references indexed in Scilit:
- Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectorsGene Therapy, 2001
- Linear DNAs Concatemerize in Vivo and Result in Sustained Transgene Expression in Mouse LiverMolecular Therapy, 2001
- Inclusion of the Hepatic Locus Control Region, an Intron, and Untranslated Region Increases and Stabilizes Hepatic Factor IX Gene Expression in Vivo but Not in VitroMolecular Therapy, 2000
- In Vivo Selection of Hepatocytes Transduced with Adeno-Associated Viral VectorsMolecular Therapy, 2000
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Sustained Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in LiverMolecular Therapy, 2000
- Persistent expression of canine factor IX in hemophilia B caninesGene Therapy, 1999
- Expression of Naked Plasmid DNA Injected into the Afferent and Efferent Vessels of Rodent and Dog LiversHuman Gene Therapy, 1997
- Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brainNature Genetics, 1994
- Hepatic Gene Therapy: Persistent Expression of Human α1-Antitrypsin in Mice after Direct Gene Delivery In VivoHuman Gene Therapy, 1992